Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.37 USD
+0.04 (1.20%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $3.38 +0.01 (0.30%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.37 USD
+0.04 (1.20%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $3.38 +0.01 (0.30%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Zacks News
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Atea Pharmaceuticals, Inc. (AVIR) and PetIQ (PETQ) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
by Zacks Equity Research
Here is how Atea Pharmaceuticals, Inc. (AVIR) and McKesson (MCK) have performed compared to their sector so far this year.
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
by Zacks Equity Research
Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.
Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Atea Pharmaceuticals, Inc. (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Atea Pharmaceuticals, Inc. (AVIR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
by Zacks Equity Research
Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.
Why Atea Pharmaceuticals (AVIR) Might Surprise This Earnings Season
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
Horizon's (HZNP) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2022. The company raises net sales guidance for 2022. Shares up.
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
by Zacks Equity Research
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.
Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.
Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.
Atea (AVIR) Dengue Candidate Gets Fast Track Designation
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) obtains Fast Track Designation in the United States for AT-752 for the treatment of dengue virus infection.
Atea Pharmaceuticals, Inc. (AVIR) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Atea Pharmaceuticals, Inc. (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Atea Pharmaceuticals, Inc. (AVIR) Surges 7.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Atea Pharmaceuticals, Inc. (AVIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Implied Volatility Surging for Atea (AVIR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Atea (AVIR) stock based on the movements in the options market lately.
Atea (AVIR) Plunges on Termination of Collaboration With Roche
by Zacks Equity Research
Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.
Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Atea (AVIR) Plunges on Oral COVID Candidate Study Failure
by Zacks Equity Research
Atea (AVIR) is developing an oral drug candidate, AT-527, as a potential treatment for COVID-19 in outpatients as well as hospitalized settings in several studies.